• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

The interplay of hypertension, ACE-2 and SARS-CoV-2: Emerging data as the "Ariadne's thread" for the "labyrinth" of COVID-19.

作者信息

Tsioufis Costas, Dimitriadis Kyriakos, Tousoulis Dimitrios

机构信息

First Cardiology Clinic, Medical School, National and Kapodistrian University of Athens, Hippokration Hospital, Athens, Greece.

First Cardiology Clinic, Medical School, National and Kapodistrian University of Athens, Hippokration Hospital, Athens, Greece.

出版信息

Hellenic J Cardiol. 2020 Jan-Feb;61(1):31-33. doi: 10.1016/j.hjc.2020.05.003. Epub 2020 May 22.

DOI:10.1016/j.hjc.2020.05.003
PMID:32450334
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7242952/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d34b/7242952/53b23559b081/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d34b/7242952/53b23559b081/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d34b/7242952/53b23559b081/gr1_lrg.jpg

相似文献

1
The interplay of hypertension, ACE-2 and SARS-CoV-2: Emerging data as the "Ariadne's thread" for the "labyrinth" of COVID-19.高血压、血管紧张素转换酶2（ACE-2）与严重急性呼吸综合征冠状病毒2（SARS-CoV-2）之间的相互作用：新出现的数据成为2019冠状病毒病（COVID-19）“迷宫”中的“阿里阿德涅之线” 。
Hellenic J Cardiol. 2020 Jan-Feb;61(1):31-33. doi: 10.1016/j.hjc.2020.05.003. Epub 2020 May 22.
2
Use of Renin-Angiotensin System Blockers During the COVID-19 Pandemic: Early Guidance and Evolving Evidence.2019冠状病毒病大流行期间肾素-血管紧张素系统阻滞剂的使用：早期指南及不断演变的证据
Can J Cardiol. 2020 Aug;36(8):1180-1182. doi: 10.1016/j.cjca.2020.05.033. Epub 2020 Jun 2.
3
ACE2 (Angiotensin-Converting Enzyme 2), COVID-19, and ACE Inhibitor and Ang II (Angiotensin II) Receptor Blocker Use During the Pandemic: The Pediatric Perspective.ACE2（血管紧张素转化酶 2）、COVID-19 以及大流行期间 ACE 抑制剂和血管紧张素 II（血管紧张素 II）受体阻滞剂的使用：儿科观点。
Hypertension. 2020 Jul;76(1):16-22. doi: 10.1161/HYPERTENSIONAHA.120.15291. Epub 2020 May 5.
4
COVID-19 Interference with Renin-Angiotensin System in the Context of Heart Failure.心力衰竭背景下COVID-19对肾素-血管紧张素系统的干扰
mBio. 2020 May 22;11(3):e00946-20. doi: 10.1128/mBio.00946-20.
5
Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19.新冠病毒病患者中的肾素-血管紧张素-醛固酮系统抑制剂
N Engl J Med. 2020 Apr 23;382(17):1653-1659. doi: 10.1056/NEJMsr2005760. Epub 2020 Mar 30.
6
COVID-19 challenging cell biology.新冠病毒对细胞生物学构成挑战。
Protoplasma. 2020 May;257(3):619-620. doi: 10.1007/s00709-020-01506-z. Epub 2020 Apr 24.
7
Diabetes mellitus: Lessons from the COVID-19 pandemic.糖尿病：来自COVID-19大流行的经验教训。
Hellenic J Cardiol. 2020 Jan-Feb;61(1):1-2. doi: 10.1016/j.hjc.2020.03.009. Epub 2020 May 18.
8
Correlation between renin-angiotensin system and Severe Acute Respiratory Syndrome Coronavirus 2 infection: What do we know?肾素-血管紧张素系统与严重急性呼吸综合征冠状病毒 2 感染的相关性：我们了解多少？
Eur J Pharmacol. 2020 Sep 15;883:173373. doi: 10.1016/j.ejphar.2020.173373. Epub 2020 Jul 15.
9
Is COVID-19 more severe in older men?新冠病毒肺炎在老年男性中病情更严重吗？
Postgrad Med J. 2020 Jul;96(1137):426. doi: 10.1136/postgradmedj-2020-137867. Epub 2020 May 13.
10
The Cross-Talk between Age, Hypertension and Inflammation in COVID-19 Patients: Therapeutic Targets.年龄、高血压与新冠肺炎患者炎症之间的相互作用：治疗靶点。
Drugs Aging. 2020 Nov;37(11):779-785. doi: 10.1007/s40266-020-00808-4. Epub 2020 Oct 21.

引用本文的文献

1
The Role of Glycemic Control in Inflammation Markers and Clinical Outcomes in Type 2 Diabetes Patients with Severe COVID-19.血糖控制在重症2型糖尿病合并新型冠状病毒肺炎患者炎症标志物及临床结局中的作用
Biomedicines. 2025 Apr 6;13(4):886. doi: 10.3390/biomedicines13040886.
2
Coronary Implications of COVID-19.新型冠状病毒肺炎的冠状动脉影响
Med Princ Pract. 2025;34(1):1-12. doi: 10.1159/000541553. Epub 2024 Sep 20.
3
Evaluation of Oxidative Stress and Endothelial Dysfunction in COVID-19 Patients.评估 COVID-19 患者的氧化应激和内皮功能障碍。

本文引用的文献

1
Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Covid-19.肾素-血管紧张素-醛固酮系统抑制剂与新冠病毒风险。
N Engl J Med. 2020 Jun 18;382(25):2441-2448. doi: 10.1056/NEJMoa2008975. Epub 2020 May 1.
2
Renin-Angiotensin-Aldosterone System Blockers and the Risk of Covid-19.肾素-血管紧张素-醛固酮系统阻滞剂与新冠病毒风险。
N Engl J Med. 2020 Jun 18;382(25):2431-2440. doi: 10.1056/NEJMoa2006923. Epub 2020 May 1.
3
Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19.心血管疾病、药物治疗与新冠病毒感染相关死亡率
Medicina (Kaunas). 2024 Jun 25;60(7):1041. doi: 10.3390/medicina60071041.
4
Clinical characteristics and outcomes of hospitalized COVID-19 patients with diabetes mellitus in East Java, Indonesia: A cross-sectional study.印度尼西亚东爪哇住院 COVID-19 合并糖尿病患者的临床特征和结局：一项横断面研究。
F1000Res. 2022 Jun 21;11:684. doi: 10.12688/f1000research.111047.1. eCollection 2022.
5
Endothelial dysfunction in acute and long standing COVID-19: A prospective cohort study.急性和长期新冠肺炎患者的内皮功能障碍：一项前瞻性队列研究。
Vascul Pharmacol. 2022 Jun;144:106975. doi: 10.1016/j.vph.2022.106975. Epub 2022 Mar 3.
N Engl J Med. 2020 Jun 18;382(25):e102. doi: 10.1056/NEJMoa2007621. Epub 2020 May 1.
4
Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19.住院 COVID-19 合并高血压患者中血管紧张素转换酶抑制剂和血管紧张素 II 受体阻滞剂的住院使用率与死亡率的关系。
Circ Res. 2020 Jun 5;126(12):1671-1681. doi: 10.1161/CIRCRESAHA.120.317134. Epub 2020 Apr 17.
5
Hypertension, the renin-angiotensin system, and the risk of lower respiratory tract infections and lung injury: implications for COVID-19.高血压、肾素-血管紧张素系统与下呼吸道感染和肺损伤风险：对 COVID-19 的影响。
Cardiovasc Res. 2020 Aug 1;116(10):1688-1699. doi: 10.1093/cvr/cvaa097.
6
Controversies of renin-angiotensin system inhibition during the COVID-19 pandemic.肾素-血管紧张素系统抑制在 COVID-19 大流行期间的争议。
Nat Rev Nephrol. 2020 Jun;16(6):305-307. doi: 10.1038/s41581-020-0279-4.
7
Coronavirus Disease 2019 (COVID-19) and Cardiovascular Disease: A Viewpoint on the Potential Influence of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers on Onset and Severity of Severe Acute Respiratory Syndrome Coronavirus 2 Infection.2019冠状病毒病（COVID-19）与心血管疾病：关于血管紧张素转换酶抑制剂/血管紧张素受体阻滞剂对严重急性呼吸综合征冠状病毒2感染的发病和严重程度潜在影响的观点
J Am Heart Assoc. 2020 Apr 7;9(7):e016219. doi: 10.1161/JAHA.120.016219. Epub 2020 Apr 1.
8
Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19.新冠病毒病患者中的肾素-血管紧张素-醛固酮系统抑制剂
N Engl J Med. 2020 Apr 23;382(17):1653-1659. doi: 10.1056/NEJMsr2005760. Epub 2020 Mar 30.
9
Can angiotensin receptor-blocking drugs perhaps be harmful in the COVID-19 pandemic?在新冠疫情期间，血管紧张素受体阻断药物是否可能有害？
J Hypertens. 2020 May;38(5):781-782. doi: 10.1097/HJH.0000000000002450.
10
Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.中国武汉成人 COVID-19 住院患者的临床病程和死亡危险因素：一项回顾性队列研究。
Lancet. 2020 Mar 28;395(10229):1054-1062. doi: 10.1016/S0140-6736(20)30566-3. Epub 2020 Mar 11.